- Division of Biomedical Science, Marian University College of Osteopathic Medicine, Indianapolis, Indiana, USA
- Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Correspondence Address:
Jonathan W. Lowery
Division of Biomedical Science, Marian University College of Osteopathic Medicine, Indianapolis, Indiana, USA
DOI:10.4103/2152-7806.192635
Copyright: © 2016 Surgical Neurology International This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.How to cite this article: King T, Caestecker Md, Lowery JW. Reply to “Bone morphogenetic protein's contribution to pulmonary artery hypertension”. Surg Neurol Int 19-Oct-2016;7:91
How to cite this URL: King T, Caestecker Md, Lowery JW. Reply to “Bone morphogenetic protein's contribution to pulmonary artery hypertension”. Surg Neurol Int 19-Oct-2016;7:91. Available from: http://surgicalneurologyint.com/surgicalint_articles/reply-bone-morphogenetic-proteins-contribution-pulmonary-artery-hypertension/
Sir,
We appreciate Dr. Epstein's raising awareness of potential complications related to the usage of recombinant Bone Morphogenetic Protein (BMP).[
In 2000, two independent groups provided the first connection between PAH pathogenesis and the BMP pathway by identifying heterozygous mutations in the gene encoding the BMP Receptor Type 2 (BMPR2) underlie a rare, familial form of PAH.[
For these reasons, we contend that the experimental evidence indicates that BMP signalling serves a protective role against the development of PAH. While we agree there are important side effects associated with the use of recombinant BMP in spine fusion, and these must be taken into consideration, it is unlikely that development of PAH is one of them.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
1. Anderson L, Lowery JW, Frank DB, Novitskaya T, Jones M, Mortlock DP. Bmp2 and Bmp4 exert opposing effects in hypoxic pulmonary hypertension. Am J Physiol Regul Integr Comp Physiol. 2010. 298: R833-42
2. Brock M, Samillan VJ, Trenkmann M, Schwarzwald C, Ulrich S, Gay RE. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur Heart J. 2014. 35: 3203-11
3. Ciuclan L, Sheppard K, Dong L, Sutton D, Duggan N, Hussey M. Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice. Am J Pathol. 2013. 183: 1461-73
4. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G. Familial primary pulmonary hypertension (gene PPH 1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000. 67: 737-44
5. Epstein NE. Commentary: Bone morphogenetic protein's contribution to pulmonary artery hypertension: Should this raise concern for patients undergoing spinal fusions with bone morphogenetic protein?. Surg Neurol Int. 2014. 5: S570-3
6. Epstein NE. Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount. Surg Neurol Int. 2013. 4: S343-52
7. Feng F, Harper RL, Reynolds PN. BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-beta-mediated pulmonary cell signalling. Respirology. 2016. 21: 526-32
8. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 2000. 26: 81-4
9. Long L, Ormiston ML, Yang X, Southwood M, Graf S, Machado RD. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nature Med. 2015. 21: 777-85
10. Lowery JW, de Caestecker MP. BMP signaling in vascular development and disease. Cytokine Growth Factor Rev. 2010. 21: 287-98
11. Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J. 2012. 39: 329-43
12. Reynolds AM, Xia W, Holmes MD, Hodge SJ, Danilov S, Curiel DT. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007. 292: L1182-92
13. Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest. 2013. 123: 3600-13
14. Yang J, Li X, Al-Lamki RS, Wu C, Weiss A, Berk J. Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2013. 33: 34-42